[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nonsegmental-vitiligo-stable\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nonsegmental-vitiligo-stable":52},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100626586",false,"NCT07437560","Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Melanotan II (Synthetic Cyclic Melanocortin Receptor Agonist) as an Adjunct to Narrowband UV-B Phototherapy in Adults With Stable Nonsegmental Vitiligo","MTII-VIT","Inclusion Criteria:\n\n* Adults aged 18-65 years able to provide informed consent.\n* Clinical diagnosis of nonsegmental vitiligo with stable disease (no new lesions and no lesion expansion) for \\>=6 months prior to screening.\n* Total body surface area involvement between 3% and 20% (inclusive), with at least two measurable target lesions suitable for standardized photography and colorimetry.\n* Willingness to undergo NB-UVB phototherapy per protocol and to avoid non-study vitiligo treatments during the study.\n* For participants of childbearing potential: agreement to use effective contraception during the study and for a protocol-specified period after the last dose.\n\nExclusion Criteria:\n\n* Segmental vitiligo as the predominant type, or rapidly progressive disease within the past 6 months.\n* Use of systemic immunosuppressive therapy, systemic corticosteroids, or JAK inhibitors within 8 weeks prior to screening (time windows may vary by drug\u002Fclass).\n* Use of topical calcineurin inhibitors or topical corticosteroids on target lesions within 2 weeks prior to baseline.\n* Prior treatment with afamelanotide or melanotan (including Melanotan II) within 6 months prior to baseline.\n* History of melanoma, dysplastic nevus syndrome, or other high-risk skin cancer history requiring close surveillance, as judged by the investigator.\n* Clinically significant uncontrolled hypertension, cardiovascular disease, or any condition that, in the investigator's judgment, increases risk with melanocortin agonist exposure.\n* Pregnant or breastfeeding.\n* Known hypersensitivity to study product components.\n* Participation in another interventional clinical trial within 30 days prior to screening.","ALL","18 Years","65 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo.",[27,28],"NonSegmental Vitiligo","Nonsegmental Vitiligo (Stable)",[30,31,32,33,34,35,36,37,38,39],"Melanotan II","MT-II","melanocortin receptor agonist","MC1R","melanogenesis","skin pigmentation","repigmentation","vitiligo","narrowband UV-B","phototherapy","RECRUITING","2026-02-22",{"date":43,"type":44},"2026-02-27","ACTUAL",{"date":46,"type":44},"2026-02-02",{"date":48,"type":21},"2028-02-17",{"name":50,"class":51},"Hudson Biotech","INDUSTRY",""]